Predictive testing

Results: 212



#Item
41Submission 16 attachment 3 - Royal College of Pathologists of Australasia - Compulsory Licensing of Patents public inquiry

Submission 16 attachment 3 - Royal College of Pathologists of Australasia - Compulsory Licensing of Patents public inquiry

Add to Reading List

Source URL: www.pc.gov.au

Language: English - Date: 2014-11-30 11:07:25
42GATE-lite for Diagnostic Test Accuracy Studies 2012 STUDY QUESTION & DESIGN: describe with PECOT STUDY NUMBERS: hang on GATE frame

GATE-lite for Diagnostic Test Accuracy Studies 2012 STUDY QUESTION & DESIGN: describe with PECOT STUDY NUMBERS: hang on GATE frame

Add to Reading List

Source URL: www.cebm.net

Language: English - Date: 2014-06-12 06:43:05
43Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
44Patient and family fact sheet  Genetic testing and screening Genetic testing is common. Almost every baby born in Australia has a blood sample taken from their heel within a few days of birth to look for the genetic cond

Patient and family fact sheet Genetic testing and screening Genetic testing is common. Almost every baby born in Australia has a blood sample taken from their heel within a few days of birth to look for the genetic cond

Add to Reading List

Source URL: www.nhmrc.gov.au

Language: English - Date: 2009-12-16 01:13:48
45HER2/neu / Biology / Breast cancer / Pharmaceutical Benefits Scheme / Health / Cancer treatments / Predictive marker / Breast cancer chemotherapy / Medicine / Trastuzumab / Ribbon symbolism

Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
46Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:41
47HER2/neu / Biology / Breast cancer / Pharmaceutical Benefits Scheme / Health / Cancer treatments / Predictive marker / Breast cancer chemotherapy / Medicine / Trastuzumab / Ribbon symbolism

Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:40
48Melanoma / Organochlorides / Organofluorides / Vemurafenib / BRAF / Sensitivity and specificity / High Resolution Melt / Positive predictive value / Genetic testing / Statistics / Biology / Biostatistics

Public Summary Document Application No. 1172 – BRAF Genetic Testing in patients with melanoma for access to proposed PBS vemurafenib Applicant: Roche Diagnostics Pty. Ltd.

Add to Reading List

Source URL: www.msac.gov.au

Language: English - Date: 2014-11-06 23:49:34
49Some Ethical Issues in Human Genetics and Genomics Fact Sheet 23 Important points Ethical issues need to be considered if the benefits are maximised and the harms minimised from the increasing ability to use genetic test

Some Ethical Issues in Human Genetics and Genomics Fact Sheet 23 Important points Ethical issues need to be considered if the benefits are maximised and the harms minimised from the increasing ability to use genetic test

Add to Reading List

Source URL: www.genetics.edu.au

Language: English
50Direct-to-Consumer Genetic Testing A Statement from the National Health and Medical Research Council (NHMRC) FEBRUARY 2014 | NHMRC REF# Direct-to-Consumer Genetic Testing – A statement from the national health and medi

Direct-to-Consumer Genetic Testing A Statement from the National Health and Medical Research Council (NHMRC) FEBRUARY 2014 | NHMRC REF# Direct-to-Consumer Genetic Testing – A statement from the national health and medi

Add to Reading List

Source URL: consultations.nhmrc.gov.au

Language: English - Date: 2014-04-16 19:57:06